270 related articles for article (PubMed ID: 21556088)
1. [Development of new therapies for multiple sclerosis].
Holmøy T; Celius EG
Tidsskr Nor Laegeforen; 2011 May; 131(8):832-6. PubMed ID: 21556088
[TBL] [Abstract][Full Text] [Related]
2. [Biological treatment of multiple sclerosis].
Sørensen PS; Sellebjerg F
Ugeskr Laeger; 2008 Jun; 170(24):2156-9. PubMed ID: 18565303
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapies in relapsing-remitting multiple sclerosis.
Marriott JJ; O'Connor PW
Rev Recent Clin Trials; 2010 Sep; 5(3):179-88. PubMed ID: 20500147
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies in the treatment of multiple sclerosis.
Di Pauli F; Berger T; Reindl M
Curr Med Chem; 2009; 16(36):4858-68. PubMed ID: 19929782
[TBL] [Abstract][Full Text] [Related]
5. [Current treatment of multiple sclerosis].
Csépány T
Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
[TBL] [Abstract][Full Text] [Related]
6. Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.
Trebst C; Voss E; Skripuletz T; Stangel M
Curr Med Chem; 2010; 17(7):640-50. PubMed ID: 20088763
[TBL] [Abstract][Full Text] [Related]
7. [Emerging therapies for multiple sclerosis].
de Lorenzo-Pinto A; Rodríguez-González CG; Ais-Larisgoitia A
Med Clin (Barc); 2013 Jan; 140(2):76-82. PubMed ID: 22766059
[TBL] [Abstract][Full Text] [Related]
8. New biological agents in the treatment of multiple sclerosis.
Buc M
Bratisl Lek Listy; 2018; 119(4):191-197. PubMed ID: 29663814
[TBL] [Abstract][Full Text] [Related]
9. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Sørensen PS
J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
[TBL] [Abstract][Full Text] [Related]
10. Emerging monoclonal antibody therapies for multiple sclerosis.
Cree B
Neurologist; 2006 Jul; 12(4):171-8. PubMed ID: 16832236
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis - established and novel therapeutic approaches.
Ehling R; Berger T; Reindl M
Cent Nerv Syst Agents Med Chem; 2010 Mar; 10(1):3-15. PubMed ID: 20236038
[TBL] [Abstract][Full Text] [Related]
12. Novel Agents for Relapsing Forms of Multiple Sclerosis.
Straus Farber R; Harel A; Lublin F
Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab: new drug. Multiple sclerosis: risky market approval.
Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
[TBL] [Abstract][Full Text] [Related]
14. [Current treatment of multiple sclerosis].
Gout O; Bensa C; Assouad R
Rev Med Interne; 2010 Aug; 31(8):575-80. PubMed ID: 20579785
[TBL] [Abstract][Full Text] [Related]
15. Treatment options for multiple sclerosis: current and emerging therapies.
Gawronski KM; Rainka MM; Patel MJ; Gengo FM
Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
[TBL] [Abstract][Full Text] [Related]
16. [Alemtuzumab and multiple sclerosis].
Nau JY
Rev Med Suisse; 2008 Nov; 4(178):2425. PubMed ID: 19051633
[No Abstract] [Full Text] [Related]
17. Current and future disease-modifying therapies in multiple sclerosis.
Lim SY; Constantinescu CS
Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
[TBL] [Abstract][Full Text] [Related]
18. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
19. [Monoclonal antibodies in [corrected] development in [corrected] multiple sclerosis].
Sastre-Garriga J; Montalban X
Neurologia; 2011 Nov; 26(9):556-62. PubMed ID: 21481981
[TBL] [Abstract][Full Text] [Related]
20. [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].
Warnke C; Kieseier BC; Zettl U; Hartung HP
Nervenarzt; 2009 Apr; 80(4):468-74. PubMed ID: 19296065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
